Palbociclib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Palbociclib |
| DrugBank ID | DB09073 |
| Brand Names (EU) | Ibrance |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.44% |
Approved Indication (EMA)
Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hyperthyroidism | 99.44% | DL |
| 2 | rheumatoid arthritis | 99.36% | DL |
| 3 | thrombotic disease | 99.32% | DL |
| 4 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 99.30% | DL |
| 5 | brachydactyly-syndactyly syndrome | 99.00% | DL |
| 6 | myeloid leukemia | 98.94% | DL |
| 7 | multiple endocrine neoplasia | 98.86% | DL |
| 8 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 98.85% | DL |
| 9 | hyperthyroxinemia | 98.78% | DL |
| 10 | Prinzmetal angina | 98.75% | DL |
| 11 | homozygous familial hypercholesterolemia | 98.70% | DL |
| 12 | vein disease | 98.55% | DL |
| 13 | thrombocytopenia | 98.51% | DL |
| 14 | female breast carcinoma | 98.39% | DL |
| 15 | Graves disease | 98.32% | DL |
| 16 | marcothrombocytopenia with mitral valve insufficiency | 98.31% | DL |
| 17 | hereditary thrombocytopenia with normal platelets | 98.31% | DL |
| 18 | transient neonatal thrombocytopenia | 98.24% | DL |
| 19 | plasma cell myeloma | 98.20% | DL |
| 20 | dense granule disease | 98.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.